{"lc": {"challenges-expected-for-novavax-covid-19-vaccine-in-usa": {"story_link": "https://www.thepharmaletter.com/article/challenges-expected-for-novavax-covid-19-vaccine-in-usa", "user_code": "GOLD_10", "age_group": "21_30", "agreed": true, "close_date_time": "2021-10-19 16:31:9", "close_timestamp": 1637339469338, "created": "19/11/2021 16:31:10", "department": "Education", "disability": false, "ease": 3, "environment": "production", "experiment_date_datepicker": "2021-11-19", "gender": "female", "id": "26cee096-5210-4369-9908-43b09418dfc2", "open_date_time": "2021-10-19 16:27:38", "open_timestamp": 1637339258184, "story_date": "2021-06-23 00:00:00", "story_source": "tpl", "story_title": "Challenges expected for Novavax' COVID-19 vaccine in USA", "summary": "The story is about the efficacy of the vaccine Novavax and the need to file for regulatory approvals and therefore be able to manufacture more of the drug.", "task_condition": "text", "task_key": "challenges-expected-for-novavax-covid-19-vaccine-in-usa", "task_level": "post_graduate_phd", "time_taken_in_seconds": 211154, "what": "The vaccine", "when_happened": "current_month", "where_location": "South Africa", "who": "Novavax, South Africa", "why": "It is about the efficacy of the vaccine"}}, "tb": {}}